NCT06797336View on ClinicalTrials.gov

A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

December 19, 2024

Primary Completion Date

December 15, 2026

Study Completion Date

June 16, 2027

Conditions
Solid Tumor
Interventions
DRUG

PT0253

PT0253 injection.

Trial Locations (5)

22031

RECRUITING

NEXT Virginia, Fairfax

78229

RECRUITING

New Experimental Therapeutics of San Antonio LLC, San Antonio

RECRUITING

START - South Texas Accelerated Research Therapeutics, LLC, San Antonio

84119

RECRUITING

START Mountain Region, West Valley City

02215

RECRUITING

Dana Farber/Massachusetts General Hospital, Inc, Boston

Sponsors
All Listed Sponsors
lead

PAQ Therapeutics, Inc.

INDUSTRY

NCT06797336 - A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors | Biotech Hunter | Biotech Hunter